LAUSR

Here we describe the effect of therapeutic plasma exchange with 5% albumin as sole replacement solution for the management of Covid‐19. A 74‐year‐old man was admitted for severe Covid‐19 acute respiratory distress syndrome. Based on the growing body of evidence that cytokine release syndrome, and especially interleukin‐6, plays a key role in critically ill Covid‐19 patients, we decided to implement therapeutic plasma exchange as a rescue therapy. The patient's clinical status rapidly improved, and biological records showed convincing results of decrease in interleukin‐6 and inflammatory parameters under treatment. This case presents a proof‐of‐concept for the use of therapeutic plasma exchange with 5% albumin as sole replacement solution in a critically ill Covid‐19 patient with cytokine release syndrome. This could constitute a major benefit in terms of security compared to long‐lasting immunosuppressive monoclonal antibodies, or to therapeutic plasma exchange with plasma as replacement fluid. Hence, we think that a further evaluation of risk‐benefit balance of this therapy in severe cases of Covid‐19 should rapidly be undertaken.